PE20210844A1 - Contorsbodies 2 + biespecificos - Google Patents
Contorsbodies 2 + biespecificosInfo
- Publication number
- PE20210844A1 PE20210844A1 PE2020000390A PE2020000390A PE20210844A1 PE 20210844 A1 PE20210844 A1 PE 20210844A1 PE 2020000390 A PE2020000390 A PE 2020000390A PE 2020000390 A PE2020000390 A PE 2020000390A PE 20210844 A1 PE20210844 A1 PE 20210844A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- target
- binding
- specific binding
- domain capable
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 8
- 102000036639 antigens Human genes 0.000 abstract 8
- 108091007433 antigens Proteins 0.000 abstract 8
- 230000027455 binding Effects 0.000 abstract 8
- 230000009870 specific binding Effects 0.000 abstract 8
- 230000004927 fusion Effects 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 125000006850 spacer group Chemical group 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a anticuerpos biespecificos ("Contorsbodies"), que consiste en dos polipeptidos de fusion y que comprende dos dominios de union a antigeno capaces de union especifica a una primera diana y un dominio de union a antigeno capaz de union especifica a una segunda diana, que comprende: (a) un primer polipeptido de fusion que comprende una primera parte de un primer dominio de union a antigeno capaz de union especifica a la primera diana, un dominio espaciador, una segunda parte de un primer dominio de union a antigeno capaz de union especifica a la primera diana y una primera parte de un dominio de union a antigeno capaz de union especifica a la segunda diana; (b) un segundo polipeptido de fusion que comprende una primera parte de un segundo dominio de union a antigeno capaz de union especifica a la primera diana, un dominio espaciador, una segunda parte del segundo dominio de union a antigeno capaz de union especifica a la primera diana y la segunda parte de un dominio de union a antigeno capaz de union especifica a la segunda diana; y en el que el dominio espaciador del primer polipeptido de fusion y el dominio espaciador del segundo polipeptido de fusion estan asociados covalentemente entre si mediante un enlace disulfuro y comprenden modificaciones que fomentan la asociacion del primer y segundo polipeptido de fusion. Tambien se refiere a un acido nucleico aislado codificante del anticuerpo biespecifico, vector o celula huesped que comprende el acido nucleico, metodo para producir un anticuerpo biespecifico, y composicion farmaceutica que comprende el anticuerpo biespecifico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199537 | 2017-11-01 | ||
| PCT/EP2018/079785 WO2019086500A2 (en) | 2017-11-01 | 2018-10-31 | Bispecific 2+1 contorsbodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210844A1 true PE20210844A1 (es) | 2021-05-10 |
Family
ID=60201893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000390A PE20210844A1 (es) | 2017-11-01 | 2018-10-31 | Contorsbodies 2 + biespecificos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12227594B2 (es) |
| EP (1) | EP3703821A2 (es) |
| JP (1) | JP7098725B2 (es) |
| KR (1) | KR20200079492A (es) |
| CN (1) | CN111182944B (es) |
| AU (1) | AU2018357923A1 (es) |
| BR (1) | BR112020006443A2 (es) |
| CA (1) | CA3076027A1 (es) |
| CL (1) | CL2020000662A1 (es) |
| CR (1) | CR20200171A (es) |
| IL (1) | IL272747B2 (es) |
| MA (1) | MA50505A (es) |
| MX (1) | MX2020004571A (es) |
| MY (1) | MY205342A (es) |
| PE (1) | PE20210844A1 (es) |
| SG (1) | SG11202002903XA (es) |
| TW (1) | TWI829658B (es) |
| WO (1) | WO2019086500A2 (es) |
| ZA (1) | ZA202001139B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3489256T3 (da) | 2014-11-14 | 2021-05-25 | Hoffmann La Roche | Antigenbindende molekyler omfattende en TNF-familieligandtrimer |
| WO2016156291A1 (en) | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
| EP3356403A2 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific antibodies specific for a costimulatory tnf receptor |
| AU2017259869A1 (en) * | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| EP3559034B1 (en) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
| MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
| EP3601345A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| CN110382542B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
| WO2018184964A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| EP3606956B1 (en) | 2017-04-04 | 2024-07-31 | F. Hoffmann-La Roche AG | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
| CA3079129C (en) * | 2017-11-01 | 2023-02-28 | F. Hoffmann-La Roche Ag | Trifab-contorsbody |
| CN111836630A (zh) | 2018-01-05 | 2020-10-27 | 希望之城 | 多特异性配体结合物 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| SG11202007961QA (en) | 2018-04-13 | 2020-09-29 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
| MX2021003548A (es) | 2018-10-01 | 2021-05-27 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap. |
| US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
| MX2021012871A (es) * | 2019-04-25 | 2021-11-17 | Hoffmann La Roche | Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. |
| BR112021020859A2 (pt) * | 2019-04-25 | 2022-01-04 | Hoffmann La Roche | Conjuntos de polipeptídeos, método para gerar um polipeptídeo, polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico e segundo polipeptídeo precursor heterodimérico |
| MX2021012931A (es) * | 2019-04-25 | 2021-11-17 | Hoffmann La Roche | Polipeptidos multiespecificos activables y terapeuticos con semivida extendida. |
| TW202108626A (zh) * | 2019-05-15 | 2021-03-01 | 日商協和麒麟股份有限公司 | 與cd40及fap結合之雙專一性抗體 |
| CN114531878A (zh) * | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
| AR121706A1 (es) * | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| KR20230012559A (ko) * | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| CR20240246A (es) * | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| WO2023245022A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target b7h3 and gd2 and uses thereof |
| AU2023326804A1 (en) * | 2022-08-18 | 2025-03-06 | Immunocore Limited | Multi-domain binding molecules |
| WO2024102436A1 (en) * | 2022-11-10 | 2024-05-16 | The Johns Hopkins University | System for modulating receptor tyrosine kinase signaling and methods of use thereof |
| WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1096187A (en) | 1977-04-18 | 1981-02-24 | Souhei Monden | Ornament adapted to be fixed by permanent magnets |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| ATE416190T1 (de) | 2003-07-04 | 2008-12-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| CN1326881C (zh) * | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体，其制备方法及用途 |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| JP5006651B2 (ja) | 2003-12-05 | 2012-08-22 | ブリストル−マイヤーズ スクウィブ カンパニー | ２型血管内皮増殖因子受容体の阻害剤 |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| EP1885399B1 (en) | 2005-05-26 | 2010-10-20 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| AU2009206089B2 (en) | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
| JP5616428B2 (ja) * | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HUE029257T2 (en) | 2009-12-29 | 2017-02-28 | Aptevo Res And Dev Llc | Heterodimer binding proteins and their use |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| KR101780131B1 (ko) | 2010-08-13 | 2017-09-19 | 로슈 글리카트 아게 | 항-fap 항체 및 이의 사용 방법 |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR101614195B1 (ko) | 2011-03-29 | 2016-04-20 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US9499608B2 (en) * | 2011-06-08 | 2016-11-22 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| DK2794905T3 (da) | 2011-12-20 | 2020-07-06 | Medimmune Llc | Modificerede polypeptider til bispecifikke antistofgrundstrukturer |
| CN114163530B (zh) | 2012-04-20 | 2025-04-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| EP3356403A2 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific antibodies specific for a costimulatory tnf receptor |
| MY193013A (en) | 2015-10-07 | 2022-09-22 | Hoffmann La Roche | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
| JP7195929B2 (ja) * | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および／または三価結合タンパク質 |
| AU2017259869A1 (en) * | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
| EP3606956B1 (en) * | 2017-04-04 | 2024-07-31 | F. Hoffmann-La Roche AG | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
| CA3079129C (en) | 2017-11-01 | 2023-02-28 | F. Hoffmann-La Roche Ag | Trifab-contorsbody |
-
2018
- 2018-10-31 MA MA050505A patent/MA50505A/fr unknown
- 2018-10-31 KR KR1020207011913A patent/KR20200079492A/ko not_active Ceased
- 2018-10-31 AU AU2018357923A patent/AU2018357923A1/en active Pending
- 2018-10-31 SG SG11202002903XA patent/SG11202002903XA/en unknown
- 2018-10-31 CN CN201880063441.2A patent/CN111182944B/zh active Active
- 2018-10-31 BR BR112020006443-2A patent/BR112020006443A2/pt not_active Application Discontinuation
- 2018-10-31 EP EP18800546.6A patent/EP3703821A2/en active Pending
- 2018-10-31 US US16/760,820 patent/US12227594B2/en active Active
- 2018-10-31 JP JP2020523704A patent/JP7098725B2/ja active Active
- 2018-10-31 MX MX2020004571A patent/MX2020004571A/es unknown
- 2018-10-31 CA CA3076027A patent/CA3076027A1/en active Pending
- 2018-10-31 MY MYPI2020002151A patent/MY205342A/en unknown
- 2018-10-31 TW TW107138691A patent/TWI829658B/zh active
- 2018-10-31 IL IL272747A patent/IL272747B2/en unknown
- 2018-10-31 WO PCT/EP2018/079785 patent/WO2019086500A2/en not_active Ceased
- 2018-10-31 PE PE2020000390A patent/PE20210844A1/es unknown
- 2018-10-31 CR CR20200171A patent/CR20200171A/es unknown
-
2020
- 2020-02-24 ZA ZA2020/01139A patent/ZA202001139B/en unknown
- 2020-03-13 CL CL2020000662A patent/CL2020000662A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3703821A2 (en) | 2020-09-09 |
| CN111182944B (zh) | 2022-11-22 |
| JP7098725B2 (ja) | 2022-07-11 |
| ZA202001139B (en) | 2021-03-31 |
| IL272747B2 (en) | 2025-04-01 |
| RU2020117441A3 (es) | 2022-04-01 |
| TW201922791A (zh) | 2019-06-16 |
| CN111182944A (zh) | 2020-05-19 |
| MA50505A (fr) | 2020-09-09 |
| TWI829658B (zh) | 2024-01-21 |
| CR20200171A (es) | 2020-06-14 |
| WO2019086500A2 (en) | 2019-05-09 |
| JP2021500898A (ja) | 2021-01-14 |
| KR20200079492A (ko) | 2020-07-03 |
| WO2019086500A3 (en) | 2019-08-29 |
| SG11202002903XA (en) | 2020-04-29 |
| US12227594B2 (en) | 2025-02-18 |
| AU2018357923A1 (en) | 2020-03-05 |
| CA3076027A1 (en) | 2019-05-09 |
| RU2020117441A (ru) | 2021-12-01 |
| US20210324108A1 (en) | 2021-10-21 |
| MX2020004571A (es) | 2020-08-24 |
| BR112020006443A2 (pt) | 2020-09-29 |
| MY205342A (en) | 2024-10-16 |
| IL272747B1 (en) | 2024-12-01 |
| CL2020000662A1 (es) | 2020-10-02 |
| IL272747A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210844A1 (es) | Contorsbodies 2 + biespecificos | |
| AU2018264321A1 (en) | Bispecific recombinant protein and use thereof | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| MX2022010487A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| FI3237005T3 (fi) | Bispesifisiä tetravalentteja vasta-aineita sekä menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| WO2017062966A8 (en) | Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof | |
| MX2024006969A (es) | Anticuerpos dlk1 y metodos de tratamiento del cancer. | |
| EA201892124A1 (ru) | Днк-конструкции антител и способы их применения | |
| EA202092928A1 (ru) | Dll3-cd3 биспецифические антитела | |
| EA202091973A1 (ru) | Конструкции слитых белков, содержащие анти-muc1 антитело и il-15 | |
| AR105633A1 (es) | Heterómeros que comprenden proteínas de fusión con dominios de anticuerpos |